182 related articles for article (PubMed ID: 2787000)
1. Serum aluminium level in the veneto chronic haemodialysis population: cross-sectional study on 1,026 patients.
Piccoli A; Andriani M; Mattiello G; Nordio M; Modena F; Dalla Rosa C
Nephron; 1989; 51(4):482-90. PubMed ID: 2787000
[TBL] [Abstract][Full Text] [Related]
2. [Aluminium in chronic renal replacement therapy patients undergoing haemodialysis in two renal units in Bogotá].
Cárdenas O; Segura O; Puentes W; Sanabria M; Nava G; Torrenegra R
Rev Salud Publica (Bogota); 2010 Aug; 12(4):669-81. PubMed ID: 21340131
[TBL] [Abstract][Full Text] [Related]
3. Level-dependent inhibitory effect of hyperaluminaemia on parathyroid hormone secretion in patients with end-stage renal failure.
Fernández E; Amoedo ML; Montoliu J
Eur J Med; 1992 Dec; 1(8):482-4. PubMed ID: 1341207
[TBL] [Abstract][Full Text] [Related]
4. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
Jarava C; Armas JR; Palma A
Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651
[TBL] [Abstract][Full Text] [Related]
5. Newcastle bone disease in Hong Kong: a study of aluminum associated osteomalacia.
Chan MK; Varghese Z; Li MK; Wong WS; Li CS
Int J Artif Organs; 1990 Mar; 13(3):162-8. PubMed ID: 2189835
[TBL] [Abstract][Full Text] [Related]
6. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity?
Jenkins DA; Gouldesbrough D; Smith GD; Cowie JF; Winney RJ
Nephrol Dial Transplant; 1989; 4(1):51-6. PubMed ID: 2494599
[TBL] [Abstract][Full Text] [Related]
7. [Hyperaluminemia in chronic hemodialysis patients. Evaluation of the respective roles of dialysate aluminum and oral aluminum hydroxide].
Tahiri Y; Moriniere P; Jaudon MC; Dkhissi H; Rosa A; Fournier A
Nephrologie; 1983; 4(3):129-33. PubMed ID: 6633778
[TBL] [Abstract][Full Text] [Related]
8. Serum aluminium in haemodialysis patients: relation to osteodystrophy, encephalopathy and aluminium hydroxide consumption.
Heaf JG; Nielsen LP
Miner Electrolyte Metab; 1984; 10(6):345-50. PubMed ID: 6503890
[TBL] [Abstract][Full Text] [Related]
9. Relative roles of intestinal absorption and dialysis-fluid-related exposure in the accumulation of aluminium in haemodialysis patients.
Mazzaferro S; Perruzza I; Costantini S; Pasquali M; Onorato L; Sardella D; Giordano R; Ciaralli L; Ballanti P; Bonucci E; Cinotti GA; Coen G
Nephrol Dial Transplant; 1997 Dec; 12(12):2679-82. PubMed ID: 9430871
[TBL] [Abstract][Full Text] [Related]
10. [Aluminum-balance during haemodialysis (author's transl)].
Graf H; Stummvoll HK; Kovarik J; Meisinger V; Wolf A; Pinggera WF
Wien Klin Wochenschr; 1980; 92(11):391-4. PubMed ID: 7424016
[TBL] [Abstract][Full Text] [Related]
11. Serum and dialysate aluminium concentration of dialysed patients with chronic renal failure determined by atomic absorption spectrometry with a graphite furnace.
Mazzeo-Farina A; Cerulli N
Clin Chim Acta; 1985 Apr; 147(3):247-54. PubMed ID: 3995774
[TBL] [Abstract][Full Text] [Related]
12. Water purification and the incidence of fractures in patients receiving home haemodialysis supervised by a single centre: evidence for "safe" upper limit of aluminium in water.
Platts MM; Owen G; Smith S
Br Med J (Clin Res Ed); 1984 Mar; 288(6422):969-72. PubMed ID: 6423163
[TBL] [Abstract][Full Text] [Related]
13. Serum aluminium concentration and aluminium deposits in bone in patients receiving haemodialysis.
Charhon SA; Chavassieux PM; Meunier PJ; Accominotti M
Br Med J (Clin Res Ed); 1985 Jun; 290(6482):1613-4. PubMed ID: 3924189
[TBL] [Abstract][Full Text] [Related]
14. Value of serum aluminium monitoring in dialysis patients: a multicentre study.
D'Haese PC; Clement JP; Elseviers MM; Lamberts LV; Van de Vyver FL; Visser WJ; De Broe ME
Nephrol Dial Transplant; 1990; 5(1):45-53. PubMed ID: 2109284
[TBL] [Abstract][Full Text] [Related]
15. The influence of aluminium on parathyroid hormone levels in haemodialysis patients.
Cannata JB; Briggs JD; Junor BJ; Beastall G; Fell GS
Proc Eur Dial Transplant Assoc; 1983; 19():244-7. PubMed ID: 6878239
[TBL] [Abstract][Full Text] [Related]
16. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload.
von Bonsdorff M; Sipilä R; Pitkänen E
Scand J Urol Nephrol Suppl; 1990; 131():49-54. PubMed ID: 2075470
[TBL] [Abstract][Full Text] [Related]
17. Aluminium load in patients with analgesic nephropathy.
Schwarz A; Kraft D; Keller F; Gawlik D; Offermann G
Miner Electrolyte Metab; 1987; 13(3):141-6. PubMed ID: 3627045
[TBL] [Abstract][Full Text] [Related]
18. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload.
D'Haese PC; Couttenye MM; Goodman WG; Lemoniatou E; Digenis P; Sotornik I; Fagalde A; Barsoum RS; Lamberts LV; De Broe ME
Nephrol Dial Transplant; 1995 Oct; 10(10):1874-84. PubMed ID: 8592597
[TBL] [Abstract][Full Text] [Related]
19. Plasma aluminium: a redundant test for patients on dialysis?
Gault PM; Allen KR; Newton KE
Ann Clin Biochem; 2005 Jan; 42(Pt 1):51-4. PubMed ID: 15802033
[TBL] [Abstract][Full Text] [Related]
20. Silicon and aluminium interactions in haemodialysis patients.
Parry R; Plowman D; Delves HT; Roberts NB; Birchall JD; Bellia JP; Davenport A; Ahmad R; Fahal I; Altmann P
Nephrol Dial Transplant; 1998 Jul; 13(7):1759-62. PubMed ID: 9681724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
